Many MedTech founders assume their company’s peak valuation will occur at regulatory clearance or product launch. In a recent article for Medical Product Outsourcing, StarFish Medical CEO Scott Phillips challenges that assumption and explains why the largest value creation in MedTech often happens after commercialization begins.

Drawing from an internal review of 75 startup programs where StarFish Medical played a significant role, Phillips examines the outcomes of 28 companies that have achieved exits so far. The data reveals a surprising pattern. None of the companies exited at the point of launch, despite the common belief that regulatory approval represents the ideal time to sell.

To better understand these outcomes, the companies were grouped into three categories: public listings, pre-commercial exits, and commercial-stage exits. Each path offers different levels of risk and reward. Some companies pursued early acquisitions prior to commercialization, particularly when addressing large markets with differentiated technologies and strong strategic interest. While these exits can generate meaningful outcomes, they often deliver more modest returns compared with later-stage transactions.

The data shows that the largest exits typically occur after companies establish commercial traction. Phillips highlights several examples where startups built early revenue, validated market demand, and reduced operational risk before attracting acquisition interest. These companies were able to demonstrate manufacturing readiness, clinical value, and a viable business model, all factors that significantly increase buyer confidence.

The analysis suggests that commercialization should not be viewed as the finish line for MedTech startups. Instead, it represents a gateway to much larger opportunities. By proving that a device can succeed in the market, companies reduce uncertainty for acquirers and strengthen their negotiating position.

Phillips concludes that founders should think carefully about their long-term strategy. While early exits are possible, the biggest outcomes tend to come from companies that continue building after launch. For many startups, the path to higher valuations lies in demonstrating commercial success rather than stopping at regulatory approval.

Explore the full discussion by visiting the complete MPO article.